Study Assessing Genetically Engineered T-Cells for Viral Infections
Phase 1
30
about 4.1 years
18+
1 site in TX
What this study is about
This trial is testing whether a new type of genetically engineered T-cells can help control viral infections in people with cancer who are also immunocompromised. The goal is to determine if these modified cells can safely and effectively target specific viruses, such as adenovirus, BK virus, cytomegalovirus, JC virus, or COVID-19, that cause infections in this population.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Virus-specific Cytotoxic T-lymphocytes
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Feasibility of administering genetically engineered glucocorticoid receptor knock out virus specific cytotoxic T-lymphocyte (CTL) lines, as indicated by Overall Survival
Oncology, Infectious